Abstract
Groups of mice infected intravenously with Candida albicans were treated intraperitoneally with amphotericin B, caspofungin, or fluconazole, starting at intervals before and after challenge. Survival was longest and tissue burdens were most reduced with early treatment, and survival times fell proportionately as treatment was delayed, reinforcing clinical recommendations for the earliest possible initiation of antifungal therapy.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amphotericin B / therapeutic use
-
Animals
-
Antifungal Agents / therapeutic use*
-
Brain / microbiology
-
Candidiasis / drug therapy*
-
Candidiasis / microbiology
-
Caspofungin
-
Colony-Forming Units Assay
-
Echinocandins
-
Female
-
Fluconazole / therapeutic use
-
Injections, Intraperitoneal
-
Lipopeptides
-
Mice
-
Mice, Inbred BALB C
-
Peptides, Cyclic / therapeutic use
-
Survival Analysis
-
Treatment Outcome
Substances
-
Antifungal Agents
-
Echinocandins
-
Lipopeptides
-
Peptides, Cyclic
-
Amphotericin B
-
Fluconazole
-
Caspofungin